While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback